Kelly, W. K., Danila, D. C., Edenfield, W. J., Aggarwal, R. R., Petrylak, D. P., Sartor, A. O., … Kouros-Mehr, H. (2020). Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Kelly, W Kevin, Daniel Costin Danila, William Jeffery Edenfield, Rahul Raj Aggarwal, Daniel Peter Petrylak, A Oliver Sartor, Christopher Joseph Sumey, et al. “Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Kelly WK, Danila DC, Edenfield WJ, Aggarwal RR, Petrylak DP, Sartor AO, et al. Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Kelly, W. Kevin, et al. “Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Kelly WK, Danila DC, Edenfield WJ, Aggarwal RR, Petrylak DP, Sartor AO, Sumey CJ, Dorff TB, Yu EY, Adra N, Waterhouse DM, Armstrong AJ, Horvath L, Pook DW, Appleman LJ, Lau A, Salvati M, Kouros-Mehr H. Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY. 2020.